Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesar Diaz-Torne

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Metabolomics : Official Journal of the Metabolomic Society|August 17, 2021
Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory studyJessica D Murillo-Saich, Cesar Diaz-Torne, M Angeles Ortiz, et al.
Joint Bone Spine|August 27, 2023
Validation of gout diagnosis in electronic primary care medical records: A population-based studyMaria A Pou, Daniel Martinez-Laguna, Jose L Estebanez, et al.
Rheumatology and Therapy|December 6, 2017
Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on PracticeFernando Perez Ruiz, Carlos A Sanchez-Piedra, Jesus T Sanchez-Costa, et al.
Annals of the Rheumatic Diseases|July 4, 2020
Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and ClevelandNeus Quilis, Paloma Vela, Boris A Blanco Cáceres, et al.
Annals of the Rheumatic Diseases|June 7, 2020
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapiesCarlos Sanchez-Piedra, Cesar Diaz-Torne, Javier Manero, et al.
The Journal of Rheumatology|February 3, 2015
Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working GroupRebecca Grainger, Nicola Dalbeth, Helen Keen, et al.
Seminars in Arthritis and Rheumatism|January 19, 2021
Outcome domains reported by patients, caregivers, healthcare professionals and stakeholders for calcium pyrophosphate deposition (CPPD): A content analysis based on semi-structured qualitative interviews from the OMERACT CPPD working groupAmy Fuller, Ken Cai, Cesar Diaz-Torne, et al.
Seminars in Arthritis and Rheumatism|May 4, 2021
Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working groupAmy Fuller, Ken Cai, Georgios Filippou, et al.
Cells|May 13, 2025
Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid ArthritisCarlos Zamora, Cesar Diaz-Torne, Maria Angels Ortiz, et al.
Journal of Ultrasound|October 18, 2024
Clinical and ultrasound optimization in rheumatoid arthritis for patients in sustained remission, can it work as a new optimization tool?Gustavo Añez, Vicenç Torrente-Segarra, María Bonet, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Metabolomics : Official Journal of the Metabolomic Society|August 17, 2021
Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory studyJessica D Murillo-Saich, Cesar Diaz-Torne, M Angeles Ortiz, et al.
Joint Bone Spine|August 27, 2023
Validation of gout diagnosis in electronic primary care medical records: A population-based studyMaria A Pou, Daniel Martinez-Laguna, Jose L Estebanez, et al.
Rheumatology and Therapy|December 6, 2017
Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on PracticeFernando Perez Ruiz, Carlos A Sanchez-Piedra, Jesus T Sanchez-Costa, et al.
Annals of the Rheumatic Diseases|July 4, 2020
Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and ClevelandNeus Quilis, Paloma Vela, Boris A Blanco Cáceres, et al.
Annals of the Rheumatic Diseases|June 7, 2020
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapiesCarlos Sanchez-Piedra, Cesar Diaz-Torne, Javier Manero, et al.
The Journal of Rheumatology|February 3, 2015
Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working GroupRebecca Grainger, Nicola Dalbeth, Helen Keen, et al.
Seminars in Arthritis and Rheumatism|January 19, 2021
Outcome domains reported by patients, caregivers, healthcare professionals and stakeholders for calcium pyrophosphate deposition (CPPD): A content analysis based on semi-structured qualitative interviews from the OMERACT CPPD working groupAmy Fuller, Ken Cai, Cesar Diaz-Torne, et al.
Seminars in Arthritis and Rheumatism|May 4, 2021
Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working groupAmy Fuller, Ken Cai, Georgios Filippou, et al.
Cells|May 13, 2025
Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid ArthritisCarlos Zamora, Cesar Diaz-Torne, Maria Angels Ortiz, et al.
Journal of Ultrasound|October 18, 2024
Clinical and ultrasound optimization in rheumatoid arthritis for patients in sustained remission, can it work as a new optimization tool?Gustavo Añez, Vicenç Torrente-Segarra, María Bonet, et al.
Pageof 5